The Life Science Rundown

The FDA Group's CEO, Nick Capman sits down with Dan Barker, CEO of Wikimotive, to explore perspectives on management and leadership. Dan shares his unique professional journey and dives into the importance of vulnerability and constant learning in leadership and management, as well as discussing other topics, including: How management can be the 'easy' side of the equation, with leadership being about ensuring management systems are built and executed effectively. Dan's non-typical career path, from cabinet maker to marketer and eventually CEO. The importance of leadership and management in enhancing people's quality of life. How good leaders and managers appreciate significant moments in their employees' lives. How enthusiasm and constant learning are important qualities for leaders. In 2023, Dan Barker was named as successor to [owner and founder] Tim Martell, accepting the role of Wikimotive’s Chief Executive Officer. Since joining the company in 2018, Dan’s extensive background in both personnel and project management, combined with his insatiable pursuit of knowledge, fueled his trajectory through nearly every role that Wikimotive had to offer. Inspiring optimizations and efficiencies along the way, the impact of Dan’s expansive knowledge, sound decision-making, and measured management style can be felt in every facet of Wikimotive’s daily operations. https://wikimotive.com/ Who is The FDA Group? The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. https://www.thefdagroup.com/

Earlier this year, Deloitte released its Global Life Sciences Outlook report, featuring a section devoted to "transforming the talent experience."  The FDA Group's CEO, Nick Capman, sat down with Larry Stevens, RAC, to unpack some of Deloitte's findings and what they might mean for life science teams looking to innovate their workforce strategies and navigate a hyper-competitive specialized labor market. Read Deloitte's full report (PDF): https://www.deloitte.com/content/dam/assets-shared/legacy/docs/perspectives/2022/gx-lshc-dei-global-life-sciences-outlook-report.pdf Some key excerpts: Page 29: _____ "Life sciences companies are still optimizing virtual ways of working, and other issues of concern for life science leaders in 2022 include: What is our talent acquisition strategy? How do we secure in-demand skills and capabilities in a competitive market? What are the “Great Resignation” effects on our company? How can we create a more meaningful talent experience? How can we become a more agile and adaptable organization?"  "Life sciences companies that want to succeed in the future of work will need to be flexible in how work is done and how talent is sourced, trained, and managed. Human resources is also undergoing a massive transformation. Instead of trying to predict the future, leaders might consider how they can develop an open culture of experimentation, learning, and iteration." Page 30: _____ "Throughout the next year, many life sciences companies will continue to grapple with how to solve these issues, and each will land in a different place on the spectrum. The 'Great Resignation' is calling for a 'Great Re-imagination', and a winning strategy includes creating value for workers as whole human beings and key stakeholders—including internal and external workers. "Successful companies are no longer concentrating on just hiring the smartest people, but rather on having access to the smartest people. New workforce ecosystems include in-house employees combined with a diverse mix of external contributors—e.g., contractors, app developers, other gig workers, external partners and suppliers, and even software bots. According to recent research from MIT Sloan Management Review and Deloitte, only 28% of global managers feel they are sufficiently preparing to manage a workforce that will rely more on external participants." "One agile strategy is to shift from a hierarchical structure to a more team- and networked-based approach that may combine internal and external workers into specialized or cross-functional teams." Page 35: _____ "According to a recent Fortune/Deloitte CEO Survey, attracting and retaining talent in a tight labor market has ascended to the top of CEOs’ list of strategic priorities. Companies should reimagine work as a landscape of tasks and skills that dynamically evolves with business priorities." _____ The FDA Group helps life science companies act on all of these recommendations, enabling RA/QA/Clinical teams to rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more and connect with us: https://www.thefdagroup.com/